Welcome to our dedicated page for Neuroone Med Technologies news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on Neuroone Med Technologies stock.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a medical technology company developing and commercializing minimally invasive, high-definition EEG recording, monitoring, ablation, drug delivery and brain stimulation solutions for neurological disorders. The NMTC news feed on Stock Titan aggregates the company’s latest press releases, conference appearances, product milestones and financial updates so readers can follow how its neuromodulation and surgical technologies are progressing.
Recent news from NeuroOne has included announcements about its OneRF Ablation System, which the company describes as an FDA 510(k)-cleared platform using the same sEEG electrode for both diagnostic and therapeutic applications, and reports of patients achieving seizure reduction or seizure freedom following treatment. The company has also issued news regarding FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System for procedures to create radiofrequency lesions for the treatment of pain or for lesioning nerve tissue for functional neurosurgical procedures, highlighting its expansion into facial pain management.
Investors and clinicians can use the NMTC news page to track quarterly and annual financial result announcements, capital raises, updates on regulatory submissions, and developments in programs such as spinal cord stimulation, basivertebral nerve ablation and sEEG-based drug delivery. NeuroOne’s disclosures also cover intellectual property milestones, including notices of allowance for patents related to thin-film electrode and neural probe manufacturing methods, as well as management and advisory appointments intended to support its clinical and commercial strategy.
By reviewing the NMTC news stream, users can see how NeuroOne communicates progress on its technology platform for conditions such as epilepsy, Parkinson’s disease, dystonia, essential tremors and chronic pain due to failed back surgeries, along with the company’s stated plans to explore additional applications. Bookmark this page to access a centralized view of NeuroOne’s official news flow as filed or released to the market.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has formed a six-member advisory board of distinguished neurosurgeons to aid in the development of its radio frequency ablation electrode. This technology aims to record and ablate brain tissue associated with seizure activity, enhancing surgical procedures for neurological disorders. CEO Dave Rosa emphasized the board's vital role in expediting technology that could improve patient outcomes and reduce costs. NeuroOne's Evo technology gained FDA clearance in November 2019, and the partnership with Zimmer Biomet offers exclusive distribution rights and potential milestone payments.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced its uplisting to The Nasdaq Capital Market, set to commence trading on May 26, 2021. This move aims to enhance the company's visibility among investors and institutional firms. CEO Dave Rosa highlighted the team's efforts over the past four years to achieve this milestone. The company specializes in minimally invasive solutions for neurological disorders, and it has secured exclusive distribution rights for its patented Evo electrode technology through a partnership with Zimmer Biomet, which may lead to significant growth opportunities.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced its participation in the Oppenheimer Medtech, Tools and Diagnostics Summit on May 26, 2021. The summit includes an on-demand presentation for registered participants and one-on-one meetings. NeuroOne focuses on minimally invasive solutions for neurological disorders, including epilepsy and Parkinson's disease. The company has received FDA clearance for its Evo cortical technology, developed in partnership with Mayo Clinic and WARF, and is committed to enhancing surgical care options.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced the appointment of Hijaz Haris as Vice President of Marketing, effective April 27, 2021. Previously a Senior Global Marketing Director at Medtronic, Haris brings over two decades of experience in neurology. CEO Dave Rosa highlighted that this appointment addresses a critical gap in leadership and aims to maximize the company's product portfolio. NeuroOne focuses on minimally invasive solutions for neurological disorders and has received FDA clearance for its Evo cortical technology.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced a reverse stock split of 1-for-3, effective March 31, 2021, at 4:01 PM ET. This move is part of their strategy to uplist to a major exchange. CEO Dave Rosa highlighted the importance of this step, alongside new institutional investments for product development. Following the split, the number of shares will decrease, impacting stock options and warrants proportionately. NeuroOne continues trading under the symbol NMTC with a new CUSIP number of 64130M 209. The company focuses on advanced solutions for neurological disorders.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced that CEO Dave Rosa will appear on the Big Biz Show on April 5, 2021, at 1:15 CST. The discussion will center on the impact of electrical stimulation on treatment modalities and NeuroOne's future role. The company focuses on developing minimally invasive solutions for neurological disorders, including epilepsy and Parkinson's disease. NeuroOne recently completed a milestone with Zimmer Biomet for exclusive distribution rights to its Evo cortical technology, which received FDA clearance in November 2019.
On February 23, 2021, NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced achieving its first performance milestone under its agreement with Zimmer Biomet, signed on July 20, 2020. The partnership grants exclusive global distribution rights for NeuroOne's Evo™ patented electrode technology and potential back-end milestone payments. CEO Dave Rosa expressed optimism for the company’s future, supported by recent financing of $12.5 million for Nasdaq uplisting and R&D acceleration. NeuroOne aims to enhance brain recording technologies for various neurological disorders.